Index RUT
P/E -
EPS (ttm) -2.79
Insider Own 29.71%
Shs Outstand 127.46M
Perf Week 3.62%
Market Cap 1.09B
Forward P/E -
EPS next Y -2.83
Insider Trans -0.05%
Shs Float 92.20M
Perf Month -17.66%
Income -341.97M
PEG -
EPS next Q -0.74
Inst Own 71.65%
Short Float 12.81%
Perf Quarter -27.19%
Sales 25.55M
P/S 42.61
EPS this Y -3.44%
Inst Trans 1.51%
Short Ratio 10.79
Perf Half Y 0.48%
Book/sh 5.90
P/B 1.41
EPS next Y 1.78%
ROA -35.19%
Short Interest 11.81M
Perf Year -44.67%
Cash/sh 5.72
P/C 1.45
EPS next 5Y -
ROE -40.18%
52W Range 5.95 - 19.23
Perf YTD -24.61%
Dividend Est. -
P/FCF -
EPS past 5Y -38.74%
ROI -42.72%
52W High -56.84%
Beta 1.63
Dividend TTM -
Quick Ratio 25.44
Sales past 5Y 319.82%
Gross Margin 79.38%
52W Low 39.50%
ATR (14) 0.54
Dividend Ex-Date -
Current Ratio 25.44
EPS Y/Y TTM -7.58%
Oper. Margin -1485.19%
RSI (14) 43.23
Volatility 5.75% 6.01%
Employees 323
Debt/Eq 0.07
Sales Y/Y TTM 1749.89%
Profit Margin -1338.60%
Recom 1.33
Target Price 23.05
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q -19.95%
Payout -
Rel Volume 0.62
Prev Close 8.16
Sales Surprise -100.69%
EPS Surprise 6.71%
Sales Q/Q -100.00%
Earnings Feb 22 AMC
Avg Volume 1.09M
Price 8.30
SMA20 -6.42%
SMA50 -11.97%
SMA200 -15.62%
Trades
Volume 679,715
Change 1.72%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-20-23 Upgrade
Jefferies
Underperform → Hold
$12.50
Apr-19-23 Upgrade
Raymond James
Outperform → Strong Buy
$29
Apr-13-23 Initiated
Raymond James
Outperform
$29
Feb-03-23 Initiated
Oppenheimer
Outperform
$33
Sep-30-22 Initiated
Barclays
Equal Weight
$23
Sep-02-22 Initiated
Stifel
Buy
$40
Jun-06-22 Initiated
Jefferies
Underperform
$13
Feb-01-22 Initiated
Berenberg
Buy
$45
Jul-21-21 Initiated
BofA Securities
Buy
$50
Dec-15-20 Reiterated
H.C. Wainwright
Buy
$54 → $57
Dec-08-20 Initiated
JMP Securities
Mkt Outperform
$66
Nov-05-20 Initiated
H.C. Wainwright
Buy
$54
Aug-10-20 Initiated
JP Morgan
Neutral
$36
Aug-10-20 Initiated
Guggenheim
Buy
$48
Aug-10-20 Initiated
Goldman
Buy
$64
Aug-10-20 Initiated
Cowen
Outperform
Show Previous Ratings
Mar-17-24 05:20PM
Mar-15-24 12:39PM
Mar-13-24 09:55AM
Feb-26-24 04:05PM
09:55AM
04:40PM
Loading…
Feb-22-24 04:40PM
04:05PM
Feb-15-24 04:05PM
10:00AM
03:29AM
Feb-01-24 04:05PM
Jan-18-24 05:37AM
Jan-08-24 07:00AM
Jan-02-24 04:05PM
Nov-30-23 09:55AM
09:55AM
Loading…
Nov-14-23 09:55AM
Nov-07-23 04:05PM
Nov-02-23 06:21PM
04:05PM
Oct-31-23 12:00PM
Oct-26-23 04:05PM
10:02AM
Oct-12-23 04:05PM
Sep-18-23 04:05PM
Aug-31-23 10:16PM
Aug-08-23 06:05PM
04:02PM
Aug-01-23 04:05PM
May-25-23 05:01PM
May-24-23 04:05PM
08:16AM
Loading…
May-18-23 08:16AM
May-04-23 07:25PM
04:05PM
Apr-27-23 04:05PM
10:03AM
Apr-21-23 02:48PM
Apr-20-23 02:20AM
Apr-19-23 07:30AM
Apr-18-23 10:40AM
Apr-14-23 05:05AM
Apr-13-23 06:12PM
03:49PM
Apr-07-23 07:44AM
Apr-06-23 09:55AM
Mar-06-23 07:30AM
Mar-01-23 07:30AM
Feb-25-23 07:31AM
Feb-23-23 05:45PM
04:05PM
Feb-21-23 10:00AM
Feb-16-23 04:05PM
10:01AM
Feb-07-23 05:01PM
Feb-02-23 07:30AM
Jan-13-23 11:11AM
Jan-03-23 07:30AM
Dec-31-22 08:53AM
Nov-24-22 08:02AM
Nov-17-22 01:58PM
Nov-07-22 07:30AM
Nov-03-22 06:35PM
04:05PM
Oct-27-22 04:05PM
Oct-14-22 10:14AM
Sep-26-22 07:30AM
Sep-23-22 07:30AM
Sep-12-22 09:30PM
07:00AM
06:30AM
Sep-11-22 09:45AM
Sep-08-22 04:06PM
10:25AM
Aug-30-22 11:15AM
Aug-25-22 02:48PM
(Investor's Business Daily)
Aug-18-22 04:05PM
Aug-04-22 04:05PM
Jul-28-22 04:05PM
Jun-27-22 06:00AM
Jun-16-22 07:30AM
May-26-22 07:30AM
May-07-22 09:59AM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-28-22 04:05PM
Feb-24-22 04:05PM
Feb-17-22 04:05PM
Feb-10-22 11:51AM
Feb-02-22 07:30AM
Jan-04-22 07:30AM
Jan-03-22 07:30AM
Dec-22-21 11:11AM
Dec-18-21 12:38AM
Dec-10-21 07:30AM
Nov-17-21 11:39AM
Nov-16-21 12:36PM
Nov-10-21 04:05PM
Nov-04-21 04:05PM
08:14AM
Oct-27-21 01:23PM
04:50AM
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bergstrom Donald A President, R&D Jan 29 '24 Sale 9.64 3,178 30,636 530,878 Jan 31 04:08 PM Catinazzo Thomas Chief Financial Officer Jan 29 '24 Sale 9.64 2,005 19,328 341,846 Jan 31 04:11 PM Adams Brian Chief Legal Officer Jan 29 '24 Sale 9.64 1,929 18,596 327,738 Jan 31 04:05 PM Rahmer Peter See remarks Jan 29 '24 Sale 9.64 1,651 15,916 514,977 Jan 31 04:14 PM Bergstrom Donald A President, R&D Dec 27 '23 Sale 11.51 977 11,245 234,056 Dec 29 04:17 PM Catinazzo Thomas Chief Financial Officer Dec 27 '23 Sale 11.51 294 3,384 143,851 Dec 29 04:22 PM Adams Brian Chief Legal Officer Dec 27 '23 Sale 11.51 294 3,384 129,667 Dec 29 04:14 PM Rahmer Peter See remarks Dec 27 '23 Sale 11.51 244 2,808 316,628 Dec 29 04:26 PM Bergstrom Donald A President, R&D Oct 30 '23 Sale 6.03 3,451 20,810 235,033 Nov 01 04:14 PM Catinazzo Thomas Chief Financial Officer Oct 30 '23 Sale 6.03 1,697 10,233 144,145 Nov 01 04:18 PM Adams Brian Chief Legal Officer Oct 30 '23 Sale 6.03 1,632 9,841 129,961 Nov 01 04:07 PM Rahmer Peter See remarks Oct 30 '23 Sale 6.03 1,354 8,165 316,872 Nov 01 04:21 PM Bergstrom Donald A President, R&D Sep 27 '23 Sale 8.38 648 5,430 238,484 Sep 29 04:52 PM Catinazzo Thomas Chief Financial Officer Sep 27 '23 Sale 8.38 294 2,464 145,842 Sep 29 04:22 PM Adams Brian Chief Legal Officer Sep 27 '23 Sale 8.38 294 2,464 131,593 Sep 29 04:10 PM Rahmer Peter See remarks Sep 27 '23 Sale 8.38 244 2,045 318,226 Sep 29 04:32 PM Bergstrom Donald A President, R&D Jul 28 '23 Sale 11.80 2,683 31,659 237,904 Jul 31 04:48 PM Catinazzo Thomas Chief Financial Officer Jul 28 '23 Sale 11.80 1,693 19,977 146,136 Jul 31 04:50 PM Adams Brian Chief Legal Officer Jul 28 '23 Sale 11.80 1,628 19,210 131,887 Jul 31 04:46 PM Rahmer Peter See remarks Jul 28 '23 Sale 11.80 1,352 15,954 316,808 Jul 31 04:52 PM Bergstrom Donald A President, R&D Jun 27 '23 Sale 12.12 647 7,842 240,587 Jun 28 05:06 PM Adams Brian Chief Legal Officer Jun 27 '23 Sale 12.12 294 3,563 133,515 Jun 28 05:02 PM Catinazzo Thomas Chief Financial Officer Jun 27 '23 Sale 12.12 294 3,563 147,829 Jun 28 05:08 PM Rahmer Peter See remarks Jun 27 '23 Sale 12.12 244 2,957 318,160 Jun 28 05:12 PM Bergstrom Donald A President, R&D Apr 28 '23 Sale 11.16 1,383 15,434 242,701 May 01 04:29 PM Adams Brian Chief Legal Officer Apr 28 '23 Sale 11.16 863 9,631 134,882 May 01 04:26 PM Catinazzo Thomas Chief Financial Officer Apr 28 '23 Sale 11.16 863 9,631 149,272 May 01 04:31 PM Rahmer Peter See remarks Apr 28 '23 Sale 11.16 739 8,247 157,504 May 01 04:33 PM
Index -
P/E -
EPS (ttm) -6.16
Insider Own 5.98%
Shs Outstand 93.73M
Perf Week 3.62%
Market Cap 12.15B
Forward P/E 11.45
EPS next Y 11.31
Insider Trans 0.92%
Shs Float 88.24M
Perf Month -5.85%
Income -535.98M
PEG -
EPS next Q -0.03
Inst Own 86.85%
Short Float 5.63%
Perf Quarter 33.68%
Sales 1.24B
P/S 9.77
EPS this Y 143.14%
Inst Trans 6.40%
Short Ratio 4.61
Perf Half Y 4.88%
Book/sh 9.17
P/B 14.12
EPS next Y 351.90%
ROA -16.77%
Short Interest 4.97M
Perf Year -1.28%
Cash/sh 17.86
P/C 7.25
EPS next 5Y -
ROE -86.15%
52W Range 55.25 - 159.89
Perf YTD 34.25%
Dividend Est. -
P/FCF -
EPS past 5Y -1.21%
ROI -25.13%
52W High -19.03%
Beta 0.94
Dividend TTM -
Quick Ratio 3.45
Sales past 5Y 32.89%
Gross Margin 84.34%
52W Low 134.32%
ATR (14) 3.77
Dividend Ex-Date -
Current Ratio 3.95
EPS Y/Y TTM 24.04%
Oper. Margin -21.54%
RSI (14) 57.99
Volatility 2.32% 3.16%
Employees 1314
Debt/Eq 1.63
Sales Y/Y TTM 33.26%
Profit Margin -43.11%
Recom 1.43
Target Price 164.33
Option/Short Yes / Yes
LT Debt/Eq 1.48
EPS Q/Q 134.77%
Payout -
Rel Volume 0.73
Prev Close 130.23
Sales Surprise 2.48%
EPS Surprise 582.15%
Sales Q/Q 53.54%
Earnings Feb 28 AMC
Avg Volume 1.08M
Price 129.46
SMA20 3.81%
SMA50 3.21%
SMA200 16.58%
Trades
Volume 786,422
Change -0.59%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-31-24 Initiated
BMO Capital Markets
Outperform
$170
Dec-13-23 Resumed
Citigroup
Buy
$113
Dec-12-23 Initiated
Deutsche Bank
Buy
$109
Nov-21-23 Initiated
Wedbush
Outperform
$224
Oct-31-23 Downgrade
Oppenheimer
Outperform → Perform
Oct-31-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$166 → $40
Jun-23-23 Downgrade
Evercore ISI
Outperform → In-line
$139
Apr-26-23 Initiated
SMBC Nikko
Outperform
$185
Apr-04-23 Initiated
Citigroup
Buy
$179
Mar-01-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$141 → $187
Dec-22-22 Reiterated
BTIG Research
Buy
$125 → $160
Dec-16-22 Upgrade
UBS
Neutral → Buy
$100 → $158
Apr-04-22 Resumed
Cantor Fitzgerald
Overweight
$140
Jan-05-22 Reiterated
Needham
Buy
$157 → $150
Dec-09-21 Upgrade
Oppenheimer
Perform → Outperform
$125
Nov-05-21 Upgrade
JP Morgan
Neutral → Overweight
$130
Sep-15-21 Upgrade
Guggenheim
Neutral → Buy
Aug-05-21 Upgrade
JP Morgan
Underweight → Neutral
$92 → $87
Jun-15-21 Initiated
BTIG Research
Buy
$110
Apr-26-21 Resumed
Credit Suisse
Neutral
$72
Show Previous Ratings
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
01:18AM
Loading…
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM
Loading…
12:00AM
Feb-28-24 06:00PM
04:23PM
(Associated Press Finance)
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
08:30AM
Feb-20-24 10:00AM
Feb-19-24 03:26AM
Feb-16-24 11:23AM
11:22AM
08:46AM
07:41AM
07:22AM
07:00AM
Loading…
07:00AM
Feb-15-24 07:45AM
Feb-11-24 01:45AM
Jan-31-24 06:29PM
Jan-29-24 07:37AM
07:12AM
07:00AM
06:50AM
Jan-26-24 05:15AM
Jan-25-24 09:45AM
Jan-22-24 05:47PM
09:55AM
09:38AM
Jan-16-24 03:57PM
09:02AM
Jan-10-24 11:43AM
06:17AM
Jan-09-24 11:22AM
10:52AM
07:15AM
Jan-08-24 11:55AM
Jan-04-24 09:55AM
Jan-02-24 08:30AM
Dec-29-23 06:27PM
08:44AM
Dec-28-23 10:07AM
Dec-27-23 06:26PM
Dec-26-23 06:56PM
Dec-22-23 02:49PM
10:15AM
08:00AM
06:33AM
Dec-17-23 09:45AM
Dec-15-23 09:55AM
Dec-12-23 12:43PM
Dec-09-23 07:00AM
Dec-01-23 11:31AM
Nov-30-23 06:34PM
Nov-29-23 09:55AM
Nov-27-23 09:50AM
Nov-24-23 10:26AM
Nov-18-23 06:49AM
Nov-16-23 06:35AM
Nov-13-23 09:55AM
07:57AM
Nov-10-23 12:58AM
Nov-09-23 10:00AM
Nov-08-23 10:15AM
Nov-07-23 11:23PM
Nov-02-23 06:25PM
12:18PM
08:30AM
12:00AM
Nov-01-23 05:03PM
(Associated Press Finance) +13.68%
04:29PM
04:05PM
Oct-31-23 07:02PM
04:19PM
04:07PM
(Investor's Business Daily)
03:03PM
(The Wall Street Journal)
11:52AM
10:26AM
10:21AM
09:38AM
09:19AM
(The Wall Street Journal)
08:01AM
07:51AM
07:19AM
(Investor's Business Daily)
Oct-30-23 04:28PM
04:10PM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boor Kathryn Jean Director Mar 11 '24 Sale 122.93 761 93,550 7,516 Mar 11 08:00 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Option Exercise 13.90 15,000 208,500 37,840 Mar 11 08:02 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Sale 123.25 15,000 1,848,795 22,840 Mar 11 08:02 PM Mayo Stephen Director Mar 05 '24 Sale 122.96 3,135 385,480 6,621 Mar 06 08:00 PM Arif Bilal Chief Tech Ops Officer Mar 01 '24 Sale 128.84 2,000 257,676 26,836 Mar 05 08:00 PM Brown Ryan Edward EVP, General Counsel Mar 01 '24 Sale 125.34 2,000 250,680 31,827 Mar 05 08:00 PM Estepan Ian Michael Chief Financial Officer Mar 01 '24 Sale 128.30 1,200 153,960 39,114 Mar 05 08:00 PM BEHRENS M KATHLEEN Director Nov 03 '23 Option Exercise 29.03 15,000 435,450 174,993 Nov 06 08:00 AM Barry Richard Director Nov 03 '23 Buy 78.81 50,000 3,940,500 140,000 Nov 06 08:00 AM INGRAM DOUGLAS S President & CEO Nov 03 '23 Buy 79.36 25,225 2,001,800 390,307 Nov 06 08:00 AM Chambers Michael Andrew Director Aug 14 '23 Buy 109.47 9,979 1,092,429 246,996 Aug 15 08:00 AM Chambers Michael Andrew Director Aug 11 '23 Buy 108.05 23,686 2,559,272 237,017 Aug 14 08:00 AM Chambers Michael Andrew Director Aug 10 '23 Buy 106.15 34,867 3,701,067 213,331 Aug 11 07:40 AM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Option Exercise 29.03 15,000 435,450 35,994 Aug 08 08:00 PM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Sale 106.72 15,000 1,600,800 20,994 Aug 08 08:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite